
A 1.6-million-birth analysis finds that adoption of a 2016 trial's antibiotic protocol climbed sharply in US hospitals, with a drop in infection rates.
Low molecular weight heparin, enoxaparin (Lovenox, Sanofi-Aventis), has a new indication, the treatment of patients with acute ST-segment elevation myocardial infarction (STEMI).






